Confronto

Amycretin vs. Pramlintid

Due peptidi a confronto — identità, base di evidenze, stato legale ed eventi avversi noti.

Identità

Categoria

Metabolico

N. CAS

nessun dato

151126-32-8

Peso molecolare

nessun dato

3949.4 g/mol

Emivita

nessun dato

Sequenza

nessun dato

Meccanismo d'azione

Amycretin

Amycretin activates both the GLP-1 and the amylin receptor in a single molecule. Both pathways independently suppress appetite and food intake — the combination is intended to amplify the effect beyond the GLP-1 axis alone.

Pramlintid

Pramlintide mimics the beta-cell hormone amylin, which is co-secreted with insulin. It slows gastric emptying, suppresses postprandial glucagon release and promotes satiety — thereby blunting post-meal blood-glucose spikes.

Base di evidenze

Evidenza più alta

RCT sull'uomo

Studi

di cui sull'uomo

Effetti registrati

Contraddizioni aperte

Eventi avversi documentati

Stato legale

Country	Amycretin	Pramlintid
Germania	Non approvato	Non approvato
Stati Uniti	Non approvato	Su prescrizione

Voci complete

Frequently asked questions

What is the difference between Amycretin and Pramlintid?: Amycretin is classified as "Metabolico", while Pramlintid is classified as "Metabolico". Amycretin: Amycretin is a unimolecular GLP-1 and amylin receptor agonist from Novo Nordisk — in development both as a once-weekly subcutaneous and a once-daily oral form for obesity and type 2 diabetes. Pramlintid: Pramlintide is a synthetic analog of the hormone amylin. It is used as an adjunct to mealtime insulin therapy in type 1 and type 2 diabetes and, among other things, slows gastric emptying. This page contrasts both neutrally and source-based — with no usage or dosing recommendation.
Which peptide is better supported by science, Amycretin or Pramlintid?: The highest available evidence level is "RCT sull'uomo" for Amycretin and "RCT sull'uomo" for Pramlintid. A higher evidence level means more robust data, but says nothing about suitability for an individual. The full body of evidence is on each peptide's own page.
What is the legal status of Amycretin and Pramlintid in Germany and the United States?: Germania: Amycretin — Non approvato, Pramlintid — Non approvato. Stati Uniti: Amycretin — Non approvato, Pramlintid — Su prescrizione. These are factual summaries with source and review date on the individual pages.

Country

Amycretin

Pramlintid

Germania

Non approvato

Stati Uniti

Non approvato

Su prescrizione

Frequently asked questions

What is the difference between Amycretin and Pramlintid?

Amycretin is classified as "Metabolico", while Pramlintid is classified as "Metabolico". Amycretin: Amycretin is a unimolecular GLP-1 and amylin receptor agonist from Novo Nordisk — in development both as a once-weekly subcutaneous and a once-daily oral form for obesity and type 2 diabetes. Pramlintid: Pramlintide is a synthetic analog of the hormone amylin. It is used as an adjunct to mealtime insulin therapy in type 1 and type 2 diabetes and, among other things, slows gastric emptying. This page contrasts both neutrally and source-based — with no usage or dosing recommendation.

Which peptide is better supported by science, Amycretin or Pramlintid?

The highest available evidence level is "RCT sull'uomo" for Amycretin and "RCT sull'uomo" for Pramlintid. A higher evidence level means more robust data, but says nothing about suitability for an individual. The full body of evidence is on each peptide's own page.

What is the legal status of Amycretin and Pramlintid in Germany and the United States?

Germania: Amycretin — Non approvato, Pramlintid — Non approvato. Stati Uniti: Amycretin — Non approvato, Pramlintid — Su prescrizione. These are factual summaries with source and review date on the individual pages.